Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1504-1509

  Combs, Stephanie E ^a   Kessel, Kerstin ^a   Habermehl, Daniel ^a   Haberer, Thomas ^a   Jäkel, Oliver ^a   Debus, Jürgen ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ALOPECIA; ANAPLASTIC GLIOMA; ANAPLASTIC MENINGIOMA; ARTICLE; BRAIN TUMOR; CANCER RECURRENCE; CHILD; COGNITION; COGNITIVE DEFECT; CRANIOPHARYNGIOMA; DIZZINESS; FATIGUE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEADACHE; HEARING IMPAIRMENT; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; ION THERAPY; MAJOR CLINICAL STUDY; MENINGIOMA; METASTASIS; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PAIN; PILOCYTIC ASTOCYTOMA; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROTON THERAPY; QUALITY OF LIFE; RADIATION SAFETY; RADIATION SICKNESS; RISK REDUCTION; SCHOOL CHILD; SEIZURE; SENSORY DYSFUNCTION; SKIN TOXICITY; SKULL BASE TUMOR; TREATMENT INDICATION; TREATMENT PLANNING; VISUAL DISORDER; CANCER GRADING; CANCER RADIOTHERAPY; CARBON ION RADIOTHERAPY; HAIR LOSS; INFANT; NAUSEA; PROTON ION RADIOTHERAPY; SKIN PAIN; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEAVY ION RADIOTHERAPY; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTON THERAPY; QUALITY OF LIFE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; SKULL BASE NEOPLASMS; YOUNG ADULT;

EID: 84884561181     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.818255     Document Type: Article

References (40)

1. Combs SE, Adeberg S, Dittmar J O, Welzel T, Rieken S, Habermehl D, et al. Skull base meningiomas: Long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol 2013;106:186-91
2. Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, et al. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 2008;89:205-10
3. Combs S E, Behnisch W, Kulozik A E, Huber P E, Debus J, Schulz-Ertner D. Intensity modulated radiotherapy (IMRT) and fractionated stereotactic radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer 2007;7:177
4. Combs SE, Thilmann C, Debus J, Schulz-Ertner D. Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT). BMC Cancer 2006;6:222
5. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D. Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol 2005;181:768-73
6. Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): Long-term results in 106 patients treateDin a single institution. Int J Radiat Oncol Biol Phys 2005;63:75-81
7. BaumaNgS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, et al. Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 1996;36:433-41
8. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 2013;52:147-52
9. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Effi cacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treateDin a single institution. J Clin Oncol 2005;23:8863-9
10. Athar BS, Paganetti H. C omparison of second cancer risk due to out-of-fi eld doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother Oncol 2011;98:87-92
11. Paganetti H. A ssessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy. Health Phys 2012;103:652-61
12. Paganetti H, Athar BS, Moteabbed M, Adams A, Schneider U, Yock TI. Assessment of radiation-induced second cancer risks in proton therapy anDiMRT for organs inside the primary radiation fi eld. Phys Med Biol 2012;57:6047-61
13. Yock T I, Caruso PA. RIsk of second cancers after photon and proton radiotherapy: A review of the data. Health Phys 2012;103:577-85
14. Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, et al. Phase I/II clinical triaLof carbon ion radiotherapy for malignant gliomas: Combined x-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:390-6
15. Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, JakeLo, et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 2007;67:171-7
16. Schulz-Ertner D, Karger C P, Feuerhake A, Nikoghosyan A, Combs SE, JakeLo, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007;68:449-57
17. Elsasser T, Kramer M, Scholz M. A ccuracy of thElocaLeffect model for the prediction of biologic effects of carbon ion beams in vitro anDin vivo. Int J Radiat Oncol Biol Phys 2008;71:866-72
18. Elsasser T, Scholz M. Improvement of thElocaLeffect model (LEM)-implications of clustered DNA damage. Radiat Prot Dosimetry 2006;122:475-7
19. Kramer M, Scholz M. T reatment planning for heavy-ion radiotherapy: Calculation and optimization of biologicallYeffective dose. Phys Med Biol 2000;45:3319-30
20. Schlampp I, Karger C P, JakeLo, Scholz M, Didinger B, Nikoghosyan A, et al. Temporal lobe reactions after radiotherapy with carbon ions: Incidence anDestimation of the relative biologicaLeffectiveness by thElocaLeffect model. Int J Radiat Oncol Biol Phys 2011;80:815-23
21. Fitzek M M, Thornton AF, Rabinov J D, Lev M H, Pardo F S, Munzenrider JE, et al. Accelerated fractionated proton/ photon irradiation to 90 cobalt graYequivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg 1999;91:251-60
22. Combs SE, Kieser M, Rieken S, Habermehl D, JakeLo, Haberer T, et al. Randomized phase II studYevaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA trial. BMC Cancer 2010;10:478
23. Combs S E, Burkholder I, Edler L, Rieken S, Habermehl D, JakeLo, et al. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial. BMC Cancer 2010;10:533
24. Rieken S, Habermehl D, Haberer T, JaekeLo, Debus J, Combs SE. Proton and carbon ion radiotherapy for primary brain tumors delivered witHactive raster scanning at the Heidelberg Ion Therapy Center (HIT): Early treatment results and study concepts. Radiat Oncol 2012;7:41
25. Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, JakeLo, et al. Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol Biol Phys 2011;81:e793-801
26. Grosu AL, Astner ST, RiedeLe, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-and L-[methyl-11C] methionine (MET)-PET in patients with braiNgliomas and metastases. Int J Radiat Oncol Biol Phys 2011;81:1049-58
27. Grosu AL, Weber W A, Franz M, Stark S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy . Int J Radiat Oncol Biol Phys 2005;63:511-9
28. Grosu AL, Weber W A, RiedeLe, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74
29. Gumprecht [29] H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB. 11C-Methionine positron emission tomography for preoperative evaluation of suggestivElowgrade gliomas. Zentralbl Neurochir 2007;68:19-23
30. Hauswald H, Rieken S, Ecker S, Kessel K A, Herfarth K, Debus J, et al. First experiences in treatment of low-grade glioma grade I anDiI with proton therapy. Radiat Oncol 2012;7:189
31. Hasegawa A, Mizoe JE, Tsujii H, Kamada T, Jingu K, Iwadate Y, et al. Experience with carbon ion radiotherapy for WHO Grade 2 diffuse astrocytomas. Int J Radiat Oncol Biol Phys 2012;83:100-6
32. Combs SE, Hartmann C, Nikoghosyan A, JakeLo, Karger CP, Haberer T, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010;95:54-9
33. Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, et al. Long-term outcome after radiotherapy in patients witHatypical and malignant meningiomas-clinical results in 85 patients treateDin a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:859-64
34. Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, et al. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment . Strahlenther Onkol 2006;182:641-6
35. Katz TS, Amdur R J, Yachnis AT, Mendenhall WM, Morris CG. Pushing the limits of radiotherapy for atypical and malignant meningioma. Am J Clin Oncol 2005;28:70-4
36. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, KrenglIm, et al. Atypical and malignant meningioma: Outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the rare cancer network. Int J Radiat Oncol Biol Phys 2008;71:1388-93
37. Combs S E, Edler L, Burkholder I, Rieken S, Habermehl D, JakeLo, et al. Treatment of patients witHatypical meningiomas SimpsoNgrade 4 and 5 witHa carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE trial. BMC Cancer 2010;10:615
38. Afshar-OromieHa, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: Comparison of (6)(8)Ga-DOTATOC PET/CT and contrastenhanced MRI. Eur J Nucl Med MoLimaging 2012;39:1409-15
39. Combs S E, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume defi nition with MRI and (68) Ga-DOTATOC-PET. Acta Oncol 2013;52:514-20
40. Combs S E, Kalbe A, Nikoghosyan A, Ackermann B, JakeLo, Haberer T, et al. Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol 2011;98:63-7